Novel |
TPTE |
transmembrane phosphatase with tensin homology |
- Synthesis of PIPs at the Golgi membrane
|
|
|
Novel |
TRIP6 |
thyroid hormone receptor interactor 6 |
|
|
|
Novel |
TUFM |
Tu translation elongation factor, mitochondrial |
- Mitochondrial translation elongation
- SARS-CoV-2 modulates autophagy
|
- Zinc
- Guanosine-5'-Diphosphate
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Combined oxidative phosphorylation deficiency (COXPD)
|
Novel |
TYK2 |
tyrosine kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Other interleukin signaling
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Evasion by RSV of host interferon responses
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Deucravacitinib
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
Novel |
VAV1 |
vav guanine nucleotide exchange factor 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- NRAGE signals death through JNK
- Regulation of actin dynamics for phagocytic cup formation
- Constitutive Signaling by Aberrant PI3K in Cancer
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CD28 dependent Vav1 pathway
- G alpha (12/13) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- VEGFR2 mediated vascular permeability
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RHOA GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOG GTPase cycle
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Potential therapeutics for SARS
- Azathioprine ADME
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
Novel |
YES1 |
YES proto-oncogene 1, Src family tyrosine kinase |
- Signaling by ERBB2
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- FCGR activation
- PECAM1 interactions
- EPH-Ephrin signaling
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- RUNX2 regulates osteoblast differentiation
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
|
ABL1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
- Regulation of actin dynamics for phagocytic cup formation
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- Myogenesis
- Myogenesis
- RHO GTPases Activate WASPs and WAVEs
- HDR through Single Strand Annealing (SSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Cyclin D associated events in G1
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- RUNX2 regulates osteoblast differentiation
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- ATP
- Imatinib
- Dasatinib
- N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
- Nilotinib
- XL228
- Bosutinib
- 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
- Myristic acid
- PD-166326
- 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
- 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
- Regorafenib
- Ponatinib
- Fostamatinib
- Brigatinib
- Radotinib
- Asciminib
- Umbralisib
|
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Chronic myeloid leukemia (CML)
|
|
ABL2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- RAC1 GTPase cycle
- RAC3 GTPase cycle
- Negative regulation of FLT3
|
- ATP
- Dasatinib
- XL228
- K-00546
- Fostamatinib
|
|
|
ARAF |
A-Raf proto-oncogene, serine/threonine kinase |
- RAF activation
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- SHOC2 M1731 mutant abolishes MRAS complex function
- Gain-of-function MRAS complexes activate RAF signaling
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
BAG1 |
BAG cochaperone 1 |
- Regulation of HSF1-mediated heat shock response
|
- (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
|
|
|
CAV1 |
caveolin 1 |
- Triglyceride catabolism
- eNOS activation
- NOSTRIN mediated eNOS trafficking
- Thyroxine biosynthesis
- Basigin interactions
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- VEGFR2 mediated vascular permeability
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOH GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- FOXO-mediated transcription of cell cycle genes
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- SARS-CoV-1 targets host intracellular signalling and regulatory pathways
- SARS-CoV-2 targets host intracellular signalling and regulatory pathways
|
|
- Congenital generalized lipodystrophy (CGL)
|
|
CAV3 |
caveolin 3 |
- Smooth Muscle Contraction
- Smooth Muscle Contraction
|
|
- Limb-girdle muscular dystrophy (LGMD)
- Caveolinopathies, including: Limb-girdle muscular dystrophy (LGMD) 1C; Rippling muscle disease (RMD); Idiopathic hyperCKemia; Distal myopathy with decreased caveolin 3; Hypertrophic cardiomyopathy (HCM)
- Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
|
|
CBL |
Cbl proto-oncogene |
- Interleukin-6 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Spry regulation of FGF signaling
- Regulation of KIT signaling
- EGFR downregulation
- TGF-beta receptor signaling activates SMADs
- Constitutive Signaling by EGFRvIII
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Negative regulation of MET activity
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by CSF1 (M-CSF) in myeloid cells
- Negative regulation of FLT3
- FLT3 signaling by CBL mutants
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
CDK14 |
cyclin dependent kinase 14 |
|
|
|
|
CDX1 |
caudal type homeobox 1 |
|
|
|
|
CEP76 |
centrosomal protein 76 |
- Regulation of PLK1 Activity at G2/M Transition
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- AURKA Activation by TPX2
|
|
|
|
CHRM3 |
cholinergic receptor muscarinic 3 |
- Muscarinic acetylcholine receptors
- Acetylcholine regulates insulin secretion
- G alpha (q) signalling events
|
- Cevimeline
- Tramadol
- Succinylcholine
- Trospium
- Ziprasidone
- Disopyramide
- Amitriptyline
- Ipratropium
- Olanzapine
- Metixene
- Terfenadine
- Clozapine
- Doxylamine
- Trihexyphenidyl
- Oxyphencyclimine
- Procyclidine
- Loxapine
- Carbamoylcholine
- Hyoscyamine
- Cyproheptadine
- Meperidine
- Imipramine
- Methscopolamine bromide
- Chlorpromazine
- Darifenacin
- Haloperidol
- Tridihexethyl
- Anisotropine methylbromide
- Nortriptyline
- Amoxapine
- Cinnarizine
- Atropine
- Thiopental
- Nicardipine
- Paroxetine
- Homatropine methylbromide
- Trimipramine
- Scopolamine
- Benzquinamide
- Propiomazine
- Dicyclomine
- Tropicamide
- Brompheniramine
- Maprotiline
- Methantheline
- Glycopyrronium
- Bethanechol
- Tolterodine
- Oxybutynin
- Promethazine
- Pilocarpine
- Doxepin
- Desipramine
- Ketamine
- Quetiapine
- Mivacurium
- Diphenidol
- Aripiprazole
- Chlorprothixene
- Pancuronium
- Pipecuronium
- Methotrimeprazine
- Tiotropium
- Solifenacin
- Isopropamide
- Acetylcholine
- Arecoline
- Mepenzolate
- ALKS 27
- Pizotifen
- Fesoterodine
- Methacholine
- Hexocyclium
- Aclidinium
- Umeclidinium
- Trimebutine
- Dosulepin
- Viloxazine
- Etoperidone
- Imidafenacin
- Butylscopolamine
- Homatropine
- Thonzylamine
- Revefenacin
- Propiverine
- Rociverine
- Diphemanil
- Aripiprazole lauroxil
|
|
|
COPA |
coat protein complex I subunit alpha |
- COPI-mediated anterograde transport
- COPI-dependent Golgi-to-ER retrograde traffic
|
|
|
|
COPB1 |
coat protein complex I subunit beta 1 |
- Neutrophil degranulation
- COPI-mediated anterograde transport
- COPI-dependent Golgi-to-ER retrograde traffic
|
|
|
|
CRK |
CRK proto-oncogene, adaptor protein |
- ARMS-mediated activation
- ARMS-mediated activation
- Downstream signal transduction
- Regulation of actin dynamics for phagocytic cup formation
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAP1 and RAC1
- MET receptor recycling
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
|
|
|